Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to enter vascular closure, but recent M&A deals have been more questionable. Haemonetics should see revenue reacceleration in FY'26, with long-term revenue growth of 6% to 7% and margin improvement driving a fair value above $100.
Haemonetics (HAE) Expands VASCADE Line With New Limited Launch
Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.
HAE vs. BSX: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
Best Momentum Stocks to Buy for June 6th
HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 6, 2024.
New Strong Buy Stocks for June 6th
HWM, LGND, MATX, SMFKY and HAE have been added to the Zacks Rank #1 (Strong Buy) List on June 6, 2024.
These 3 Companies Boast Bright Outlooks
Listening to the Zacks Rank can consistently result in market-beating gains, as positive earnings estimate revisions provide the fuel needed for shares to move higher.
Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Haemonetics (HAE) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List
Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.
